Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019698 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL30775720 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL30775787 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL29355417 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL460037 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL1659938 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL30775723 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL18746282 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL460038 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 | |
| SCHEMBL1659934 | 1.00 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | claimed |
| WO-2020191359-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-09-24 | — | — | WO | claimed |
| US-20180200275-A1 | METHOD AND THE USE TO IMPROVE ORAL ABSORPTION OF NICOTINAMIDE AND NICOTINAMIDE RIBOSIDE | Better Standing Company Inc. (US) | 2018-07-19 | — | — | US | claimed |
| US-20240216412-A1 | OXIDIZED NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) PRECURSOR TREATMENT FOR HEART FAILURE ALLEVIATION INDEPENDENT OF MITOCHONDRIAL PROTEIN DEACETYLATION | UNIVERSITY OF WASHINGTON (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230263817-A1 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | UNIVERSITY OF WASHINGTON (US) | 2023-08-24 | — | — | US | disclosed |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2020191359-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-2488010-A1 | MANIPULATION OF FLAVONOID BIOSYNTHETIC PATHWAY | Agriculture Victoria Services Pty Ltd (AU) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011044632-A1 | MANIPULATION OF FLAVONOID BIOSYNTHETIC PATHWAY | AGRICULTURE VICTORIA SERVICES PTY LTD (AU) | 2011-04-21 | — | — | WO | disclosed |
| US-20080070874-A1 | using retinoid or tetracycline as bactericide, benzoyl peroxide as metalloproteinases (MMPs) and neutrophil elastase inhibitors; antiscarring agents; reduction in procollagen biosynthesis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2008-03-20 | — | — | US | disclosed |
| US-7268148-B2 | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-09-11 | — | — | US | disclosed |
| US-20040235950-A1 | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes | REGENTS OF THE UNIVERSITY OF MICHIGAN, THE | 2004-11-25 | — | — | US | disclosed |
| EP-1284721-A2 | COMPOSITIONS AND METHODS FOR USE AGAINST ACNE-INDUCED INFLAMMATION AND DERMAL MATRIX-DEGRADING ENZYMES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020106339-A1 | Compositions and methods using direct MMP inhibitors for inhibiting photoaging of skin | FISHER GARY J (US) | 2002-08-08 | — | — | US | disclosed |
| US-6365630-B1 | Compositions and methods for inhibiting photoaging of skin | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-04-02 | — | — | US | disclosed |
| WO-2001089502-A2 | COMPOSITIONS AND METHODS FOR USE AGAINST ACNE-INDUCED INFLAMMATION AND DERMAL MATRIX-DEGRADING ENZYMES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2001-11-29 | — | — | WO | disclosed |
| US-6130254-A | Methods for inhibiting photoaging of skin | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0998251-A4 | COMPOSITIONS AND METHODS FOR INHIBITING PHOTOAGING OF SKIN | UNIV MICHIGAN (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0998251-A2 | COMPOSITIONS AND METHODS FOR INHIBITING PHOTOAGING OF SKIN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998055075-A2 | COMPOSITIONS AND METHODS FOR INHIBITING PHOTOAGING OF SKIN | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263817-A1 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | NAMPT, NNT, NQO1 | CYP3A4 421/4885KDM4E 4593/4885HSD17B10 1135/4885 |
| US-20180200275-A1 | METHOD AND THE USE TO IMPROVE ORAL ABSORPTION OF NICOTINAMIDE AND NICOTINAMIDE RIBOSIDE | SIRT6, NADK, SIRT1 | CYP3A4 1028/4885KDM4E 4762/4885HSD17B10 3067/4885 |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | CYP3A4 3656/4885KDM4E 3102/4885HSD17B10 2494/4885 |
| US-20240216412-A1 | OXIDIZED NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) PRECURSOR TREATMENT FOR HEART FAILURE ALLEVIATION INDEPENDENT OF MITOCHONDRIAL PROTEIN DEACETYLATION | NAMPT, SIRT3, NDUFAB1 | CYP3A4 4074/4885KDM4E 3681/4885HSD17B10 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.